<html>
<head>PUBMED IDs for hCD40L</head>
<body bgcolor='#C5F0F2'><h1>hCD40L</h1><a href='https://pubmed.ncbi.nlm.nih.gov/11426465/'>Autologous antileukemic immune response induced by chronic lymphocytic leukemia B cells expressing the CD40 ligand and interleukin 2 transgenes.</a> June 28  2001<br><a href='https://pubmed.ncbi.nlm.nih.gov/11477458/'>Transgenic expression of CD40L and interleukin-2 induces an autologous antitumor immune response in patients with non-Hodgkin's lymphoma.</a> July 31  2001<br><a href='https://pubmed.ncbi.nlm.nih.gov/11495701/'>Adenovector-induced expression of human-CD40-ligand (hCD40L) by multiple myeloma cells. A model for immunotherapy.</a> August 10  2001<br><a href='https://pubmed.ncbi.nlm.nih.gov/12070030/'>Activation-induced cell death of aggressive histology lymphomas by CD40 stimulation: induction of bax.</a> June 19  2002<br><a href='https://pubmed.ncbi.nlm.nih.gov/12718765/'>Bystander transfer of functional human CD40 ligand from gene-modified fibroblasts to B-chronic lymphocytic leukemia cells.</a> April 30  2003<br><a href='https://pubmed.ncbi.nlm.nih.gov/16249392/'>Immunotherapy of high-risk acute leukemia with a recipient (autologous) vaccine expressing transgenic human CD40L and IL-2 after chemotherapy and allogeneic stem cell transplantation.</a> October 27  2005<br><a href='https://pubmed.ncbi.nlm.nih.gov/19461675/'>Adenovirus delivery of human CD40 ligand gene confers direct therapeutic effects on carcinomas.</a> January 1  2009<br><a href='https://pubmed.ncbi.nlm.nih.gov/19609245/'>Generation of human dendritic cells that simultaneously secrete IL-12 and have migratory capacity by adenoviral gene transfer of hCD40L in combination with IFN-gamma.</a> October 9  2009<br><a href='https://pubmed.ncbi.nlm.nih.gov/19836045/'>Mucosal immunity induced by adenovirus-based H5N1 HPAI vaccine confers protection against a lethal H5N2 avian influenza virus challenge.</a> December 24  2009<br><a href='https://pubmed.ncbi.nlm.nih.gov/20072155/'>Selective elimination of a chemoresistant side population of B-CLL cells by cytotoxic T lymphocytes in subjects receiving an autologous hCD40L/IL-2 tumor vaccine.</a> March 31  2010<br><a href='https://pubmed.ncbi.nlm.nih.gov/20423644/'>[Construction and identification of recombinant adenovirus vector expressing IkappaBalpha-IRES2-shCD40L].</a> August 10  2010<br><a href='https://pubmed.ncbi.nlm.nih.gov/22396493/'>Immune response is an important aspect of the antitumor effect produced by a CD40L-encoding oncolytic adenovirus.</a> August 18  2012<br><a href='https://pubmed.ncbi.nlm.nih.gov/23994887/'>Phase II trial of a GM-CSF-producing and CD40L-expressing bystander cell line combined with an allogeneic tumor cell-based vaccine for refractory lung adenocarcinoma.</a> April 9  2013<br><a href='https://pubmed.ncbi.nlm.nih.gov/24305418/'>CD40 ligand and tdTomato-armed vaccinia virus for induction of antitumor immune response and tumor imaging.</a> October 28  2013<br><a href='https://pubmed.ncbi.nlm.nih.gov/26586612/'>Cloning and high level expression of the biologically active extracellular domain of Macaca mulatta CD40 in Pichia pastoris.</a> October 25  2015<br><a href='https://pubmed.ncbi.nlm.nih.gov/27876704/'>Pancreatic carcinoma-specific immunotherapy using novel tumor specific cytotoxic T cells.</a> November 24  2016<br><a href='https://pubmed.ncbi.nlm.nih.gov/28344872/'>Intravenously usable fully serotype 3 oncolytic adenovirus coding for CD40L as an enabler of dendritic cell therapy.</a> March 28  2017<br></body></html>
